Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more

Ovarian Cancer Patients Undertested for Mutations that Could Guide Clinical Care

April 9, 2019 4:00 pm

By Krista Conger

A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.

Fewer than a quarter … Read more

23andMe DTC Breast and Ovarian Cancer Risk Test Misses Almost 90 Percent of BRCA Mutation Carriers

April 5, 2019 5:00 pm

By Julia Karow

A study led by researchers at Invitae has found that 23andMe’s direct-to-consumer BRCA test, which tests for three common variants in the BRCA1 and BRCA2 genes and is authorized by the US Food and Drug Administration, misses … Read more

‘End of the Road’ for Trabectedin in Ovarian Cancer?

March 21, 2019 7:00 pm

By Ian Ingram

Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.

Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more

SGO 2019: Less Worry, More Symptoms and Regret With Risk-Reducing Salpingo-Oophorectomy

March 20, 2019 5:00 pm

By Christina Bennett, MS

Women at increased risk for hereditary ovarian cancer who underwent risk-reducing salpingo-oophorectomy experienced less worry but worse menopausal symptoms and more regret compared with those who underwent salpingectomy with delayed oophorectomy, the Women Choosing Surgical Prevention … Read more

When PARP Inhibitors Fail in Ovarian Cancer

March 18, 2019 6:00 pm

By Ian Ingram

Study identifies subgroup for whom another go could be worthwhile.

Lack of response to a PARP inhibitor in epithelial ovarian cancer didn’t necessarily mean patients were resistant to all such agents, a small retrospective study indicated.

Among … Read more

Only 18% of People With Breast and Ovarian Cancer Genes Knew They Were Carriers, Study Found. How Can We Make DNA Screening Work Better?

February 7, 2019 5:00 pm

By Michael Murray

There are diseases and health conditions that are essentially invisible to us until it is too late.

When those problems are life-threatening, such as cancer, and if there is a period when something could be done, then … Read more

Drug Target Identified for Chemotherapy-Resistant Ovarian, Breast Cancer

February 4, 2019 5:00 pm

By Tamara Bhandari

Study finds mimic for BRCA genes that could be targeted to improve treatment

People who inherit a faulty copy of the so-called “breast cancer genes” BRCA1 and BRCA2 are at high risk of cancer. About 10 percent … Read more

FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers

December 19, 2018 5:00 pm

By Brielle Benyon

The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a

Read more

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

September 28, 2018 8:37 pm

The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more

Study Cracks Open the Secrets of the Cancer-Causing BRCA1 Gene

September 12, 2018 12:21 am

By Sharon Begley

Lawsuits didn’t do it, public shaming didn’t do it, patients and doctors banding together to “free the data” couldn’t do it: For 22 years Myriad Genetics, one of the oldest genetic testing companies, has refused to make … Read more

Study: Cancer-related genetic testing is rare for women on Medicare

August 20, 2018 6:28 pm

By Health Day News

Testing for gene mutations linked to breast and ovarian cancer is rare among some Medicare patients who have the cancers and qualify for such tests, a new study finds.

Researchers analyzed data from 12 southeastern states … Read more

Genetic Screening Can Inform Women of Their Breast and Ovarian Cancer Risks

July 6, 2018 7:21 pm

One of the most unsettling aspects of cancer is the unknown.

There is the unknown of what is in store for you if you receive a diagnosis of cancer. But on a larger scale, we all

Read more

Busting Myths Surrounding Cancer and Genetic Testing

April 18, 2018 12:02 am

While only 5 percent to 10 percent of cancers are caused by an inherited gene mutation, genetic testing may benefit people with a strong history of family cancer, an expert in genetics suggests.

This is especially true in families with … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

Could New Approach Stave Off Ovarian Cancer? Study May Tell

March 16, 2018 7:08 pm

Anna Hargrove learned she carries a genetic mutation that predisposes women toward breast and ovarian cancer at 27, which was no surprise given her family history.

Hargrove, cautious by nature, did what a lot of women with the mutation do: … Read more

FDA Approves 23andMe Cancer Test For BRCA Genes

March 12, 2018 8:33 pm

The home DNA testing company 23andMe has received approval from the US Food and Drug Administration (FDA) to test for three genetic mutations in two genes that you have probably heard of if you know who Angelina Jolie is, BRCA1 … Read more

Screening Beyond Those With Cancer History May Be More Effective

February 12, 2018 10:32 pm

As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer InstituteRead more

BRCA1 Methylation Tied to Ovarian Cancer Risk

January 18, 2018 4:26 am

BRCA1 mutations are well-known to predispose to ovarian cancer risk. But now a new study, appearing in the Annals of Internal Medicine, suggests that methylation of normal BRCA1 genes might be a major ovarian cancer risk factor. In this Read more

Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

January 15, 2018 6:18 pm

Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).

Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more